An Akt/hypoxia-inducible factor-1α/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells

Clinical Cancer Research

Volumn 15, Issue 10, 2009, Pages 3462-3471

  Chi, Keung Lau ^a   Zhen, Fan Yang ^a   Ho, David W ^a   Ng, Michael N ^a   Yeoh, George C T ^b   Poon, Ronnie T P ^a   Sheung, Tat Fan ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; CISPLATIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PLATELET DERIVED GROWTH FACTOR BB; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOCRINE EFFECT; CANCER CELL; CANCER CHEMOTHERAPY; CARCINOGENICITY; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; HEPATIC ARTERY LIGATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO CULTURE; LIVER CELL CARCINOMA; MALE; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL; RAT; STEM CELL; TUMOR CELL; TUMOR GROWTH; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL HYPOXIA; CELL LINE; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEIN V-AKT; OXYGEN; PLATELET-DERIVED GROWTH FACTOR; RATS; RATS, INBRED BUF; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66149180568     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2127     Document Type: Article

References (45)

1. el-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001;5:87-107, vi.
2. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437-447 (Pubitemid 38745529)
3. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739 (Pubitemid 34607087)
4. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-1171 (Pubitemid 34454013)
5. Comerford KM, Cummins EP, Taylor CT. c-Jun NH2-terminal kinase activation contributes to hypoxia-inducible factor 1α-dependent P-glycoprotein expression in hypoxia. Cancer Res 2004;64:9057-9061 (Pubitemid 39665517)
6. Krishnamurthy P, Ross DD, Nakanishi T, et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 2004;279:24218-24225 (Pubitemid 38725283)
7. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 2001;18:243-259 (Pubitemid 34044509)
8. Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001;2:769-776 (Pubitemid 33679839)
9. Thompson JE, Thompson CB. Putting the rap on Akt. J Clin Oncol 2004;22:4217-4226 (Pubitemid 41185193)
10. Fontijn D, Adema AD, Bhakat KK, Pinedo HM, Peters GJ, Boven E. O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells. Mol Cancer Ther 2007;6:2807-2815 (Pubitemid 350058159)
11. Katayama R, Huelsmeyer MK, Marr AK, Kurzman ID, Thamm DH, Vail DM. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. Cancer Chemother Pharmacol 2004;54:25-33. (Pubitemid 38858362)
12. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002;62:3387-3394 (Pubitemid 34651384)
13. Sullivan R, Pare GC, Frederiksen LJ, Semenza GL, Graham CH. Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther 2008;7:1961-1973
14. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998;394:485-490 (Pubitemid 28373960)
15. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657-667 (Pubitemid 39063268)
16. + cancer stem cells in human liver cancer. Cancer Cell 2008;13:153-166
17. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells - perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006;66:9339-9344 (Pubitemid 44623625)
18. Evarts RP, Nagy P, Nakatsukasa H, Marsden E, Thorgeirsson SS. In vivo differentiation of rat liver oval cells into hepatocytes. Cancer Res 1989;49:1541-1547
19. Germain L, Noel M, Gourdeau H, Marceau N. Promotion of growth and differentiation of rat ductular oval cells in primary culture. Cancer Res 1988;48:368-378 (Pubitemid 18045773)
20. Tian YW, Smith PG, Yeoh GC. The oval-shaped cell as a candidate for a liver stem cell in embryonic, neonatal and precancerous liver: identification based on morphology and immunohistochemical staining for albumin and pyruvate kinase isoenzyme expression. Histochem Cell Biol 1997;107:243-250 (Pubitemid 27132693)
21. Dumble ML, Croager EJ, Yeoh GC, Quail EA. Generation and characterization of p53 null transformed hepatic progenitor cells: oval cells give rise to hepatocellular carcinoma. Carcinogenesis 2002;23:435-445 (Pubitemid 34257623)
22. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 1969;27:502-522
23. Wataha JC, Lewis JB, Lockwood PE, Rakich DR. Effect of dental metal ions on glutathione levels in THP-1 human monocytes. J Oral Rehabil 2000;27:508-516
24. Jin HM, Robinson DF, Liang Y, Fahl WE. SIS/PDGF-B promoter isolation and characterization of regulatory elements necessary for basal expression of the SIS/PDGF-B gene in U2-OS osteosarcoma cells. J Biol Chem 1994;269:28648-28654 (Pubitemid 24366698)
25. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001;21:3995-4004.
26. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541-1545 (Pubitemid 30183422)
27. Calvani M, Rapisarda A, Uranchimeg B, Shoemaker RH, Melillo G. Hypoxic induction of an HIF-1α-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood 2006;107:2705-2712
28. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1α and insulin-like growth factor 2. Cancer Res 1999;59:3915-3918 (Pubitemid 29393552)
29. Krishnamachary B, Berg-Dixon S, Kelly B, et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 2003;63:1138-1143 (Pubitemid 36278449)
30. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732 (Pubitemid 37328811)
31. Sosman JA, Puzanov I, Atkins MB. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res 2007;13:764-69s. (Pubitemid 46220112)
32. Yoshida D, Kim K, Noha M, Teramoto A. Hypoxia inducible factor 1-α regulates of platelet derived growth factor-B in human glioblastoma cells. J Neurooncol 2006;76:13-21. (Pubitemid 43115754)
33. Bos R, van Diest PJ, de Jong JS, van der Groep P, van der Valk P, van der Wall E. Hypoxia-inducible factor-1α is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 2005;46:31-36
34. Zhang SX, Gozal D, Sachleben LR, Jr., Rane M, Klein JB, Gozal E. Hypoxia induces an autocrine-paracrine survival pathway via platelet-derived growth factor (PDGF)-B/PDGF-β receptor/phosphatidylinositol 3-kinase/Akt signaling in RN46A neuronal cells. FASEB J 2003;17:1709-1711
35. Vince JE, Chau D, Callus B, et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-2 complex to sensitize tumor cells to TNFα. J Cell Biol 2008;182:171-184
36. Tam KH, Yang ZF, Lau CK, Lam CT, Pang RW, Poon RT. Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. Cancer Lett 2009;273:201-209
37. Land SC, Tee AR. Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 2007;282:20534-20543 (Pubitemid 47100043)
38. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006;355:1253-1261 (Pubitemid 44427449)
39. Yang ZF, Poon RT, To J, Ho DW, Fan ST. The potential role of hypoxia inducible factor 1α in tumor progression after hypoxia and chemotherapy in hepatocellular carcinoma. Cancer Res 2004;64:5496-5503 (Pubitemid 39006574)
40. Scala S, Akhmed N, Rao US, et al. P-glycoprotein substrates and antagonists cluster into two distinct groups. Mol Pharmacol 1997;51:1024-1033 (Pubitemid 27249136)
41. Mitry RR, Sarraf CE, Havlik R, Habib NA. Detection of adenovirus and initiation of apoptosis in hepatocellular carcinoma cells after Ad-p53 treatment. Hepatology 2000;31:885-889 (Pubitemid 30169935)
42. Bush JA, Li G. Cancer chemoresistance: the relationship between p53 and multidrug transporters. Int J Cancer 2002;98:323-330 (Pubitemid 34188673)
43. O'Brien ML, Tew KD. Glutathione and related enzymes in multidrug resistance. Eur J Cancer 1996;32A:967-978 (Pubitemid 26191764)
44. Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 2007;12:853-859 (Pubitemid 47554628)
45. Lau CK, Yang ZF, Lam SP, et al. Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma. Cancer Biol Ther 2007;6:1900-1907